Extended Mycophenolate Mofetil Administration Beyond Day 30 in Allogeneic Hematopoietic Stem Cell Transplantation as Preemptive Therapy for Severe Graft-Versus-Host Disease

Transplantation Proceedings

Volumn 41, Issue 9, 2009, Pages 3873-3876

  Nishikawa, S ^a   Okamura, A ^a   Yamamori, M ^a   Minagawa, K ^a   Kawamori, Y ^a   Kawano, Y ^a   Kawano, H ^a   Ono, K ^a   Katayama, Y ^a   Shimoyama, M ^a   Matsui, T ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION;

ADULT; AGED; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; MYELODYSPLASTIC SYNDROMES; SAFETY; TACROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 71749119355     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.231     Document Type: Article

References (17)

1. Bolwell B., Sobecks R., Pohlman B., et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 34 (2004) 621
2. Osunkwo I., Bessmertny O., Harrison L., et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 10 (2004) 246
3. Neumann F., Graef T., Tapprich C., et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 35 (2005) 1089
4. Jacobson P., Rogosheske J., Barker J.N., et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 78 (2005) 486
5. Giaccone L., McCune J.S., Maris M.B., et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 106 (2005) 4381
6. Nash R.A., Johnston L., Parker P., et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 11 (2005) 495
7. Maris M.B., Sandmaier B.M., Storer B.E., et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 12 (2006) 454
8. Nieto Y., Patton N., Hawkins T., et al. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biol Blood Marrow Transplant 12 (2006) 217
9. Kawamori Y., Yakushijin K., Okamura A., et al. Successful engraftment in reduced-intensity cord blood transplantation (CBT) as a salvage therapy for graft failure after primary CBT in adults. Transplantation 83 (2007) 1281
10. Brunstein C.G., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 110 (2007) 3064
11. Pérez-Simón J.A., Martino R., Caballero D., et al. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 14 (2008) 664
12. Okamura A., Yamamori M., Shimoyama M., et al. Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation. Int J Hamatol 88 (2008) 104
13. Shaw L.M., Holt D.W., Oellerich M., et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 23 (2001) 305
14. Ng J., Rogosheske J., Barker J., et al. A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). Ther Drug Monit 28 (2006) 394
15. van Hest R.M., Doorduijn J.K., de Winter B.C., et al. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. Ther Drug Monit 29 (2007) 353
16. Lange S., Mueller S.C., Altmann S., et al. Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 41 (2008) 667
17. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995) 825